Press Latest Release http://www.csl.com.au CSL News Tue, 30 Aug 2016 00:00:00 -0500 FDA Accepts CSL Behring’s BLA for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has accepted for review CSL Behring’s Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252903133838/prdetail.htm 1252903133838 Wed, 17 Aug 2016 02:00:00 -0500 Full Year Result 2016 CSL Delivers Another Strong Performance thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,242 million for the full year ended 30 June 2016.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252903068442/prdetail.htm 1252903068442 Wed, 17 Aug 2016 00:00:00 -0500 CSL Announces Changes to the Board thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Dr Tadataka “Tachi” Yamada KBE has been appointed a Director effective from 1 September 2016. The Company also announced that Mr John Akehurst, has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 12 October 2016.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252903068528/prdetail.htm 1252903068528 Mon, 04 Jul 2016 00:00:00 -0500 CSL to Support new Biopharmaceutical Training Centre at UQ thumbnail CSL is pleased to announce it will be an inaugural partner of the new Australian Research Council Industrial Transformation Training Centre for Biopharmaceutical Innovation to be established at the University of Queensland.   http://www.csl.com.au/Newsroom/CSL-to-Support-new-Biopharmaceutical-Training-Centre-at-UQ.htm 1252902853562 Fri, 10 Jun 2016 00:00:00 -0500 CSL Behring is 2016 ‘Victorian Manufacturer of the Year’ thumbnail CSL Behring’s Australian facility was last night awarded ‘2016 Victorian Manufacturer of the Year’ in the Large Business category at the Victorian Manufacturing Hall of Fame Awards.   http://www.csl.com.au/Newsroom/CSLBehring-2016-Victorian-Manufacturer.htm 1252902785464 Mon, 06 Jun 2016 00:00:00 -0500 Seqirus donates vaccines to Fiji to alleviate increase in influenza picture CSL’s subsidiary, Seqirus, today announced the donation of 20,000 doses of seasonal influenza vaccine to the people of Fiji in order to help alleviate a spike in cases of severe influenza.   http://www.csl.com.au/Newsroom/Seqirus-donates-vaccines-to-Fiji-to-alleviate-increase-in-influenza.htm 1252902766878 Wed, 01 Jun 2016 00:00:00 -0500 CSL Centenary Fellowships: Call for Applications thumbnail CSL is now calling for applications for the two inaugural fellowships to be awarded in late 2016, for commencement on 1 January 2017.   http://www.csl.com.au/Newsroom/CSL-Centenary-Fellowships_Call-for-Applications.htm 1252902740525 Thu, 26 May 2016 00:00:00 -0500 AFSTYLA® (rFVIII-Single Chain) – FDA approval thumbnail CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemophilic Factor (Recombinant), Single Chain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252902725475/prdetail.htm 1252902725475 Tue, 24 May 2016 00:00:00 -0500 FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) - FDA Approval thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved Seqirus’ FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252902716603/prdetail.htm 1252902716603 Thu, 12 May 2016 00:00:00 -0500 IDELVION® (rFIX-FP) - European Commission Approval thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that, following the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation to grant marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B in late February 2016, the European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252902671407/prdetail.htm 1252902671407 Mon, 25 Apr 2016 00:00:00 -0500 CSL Celebrates 100 Years of Operation thumbnail Australia’s largest and most successful biotechnology company, CSL, will officially celebrate 100 years of operation on 25th April 2016.   http://www.csl.com.au/Newsroom/CSL-Celebrates-100-Years-Operation.htm 1252902614946 Thu, 14 Apr 2016 00:00:00 -0500 CSL Announces $25 million Centenary Fellowship Program article image CSL is proud to announce the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia.   http://www.csl.com.au/Newsroom/CSL-Announces-25million-Centenary-Fellowship-Program.htm 1252902563233 Mon, 07 Mar 2016 00:00:00 -0500 Expanded Bio21 to house global research hub thumbnail The University of Melbourne’s internationally recognized Bio21 Molecular Science and Biotechnology Institute is to be substantially expanded and will house CSL’s Global Research and Translational Medicine Hub.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252902344770/prdetail.htm 1252902344770 Mon, 07 Mar 2016 00:00:00 -0500 IDELVION® (rFIX-FP) – FDA approval thumbnail CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring’s novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252902343715/prdetail.htm 1252902343715 Mon, 29 Feb 2016 00:00:00 -0500 IDELVION® (rFIX-FP) - CHMP recommendation thumbnail CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252902269974/prdetail.htm 1252902269974 Tue, 16 Feb 2016 00:00:00 -0500 CSL Appoints New Director thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that Dr Megan Clark AC has been appointed as a Director of the Company effective from 16 February 2016.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252902212329/prdetail.htm 1252902212329 Tue, 16 Feb 2016 00:00:00 -0500 Half Year Result 2016 CSL Delivers Exceptional Performance thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1 NPAT grew 7% and EPS grew 9%, at constant currency2.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252902209100/prdetail.htm 1252902209100